Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525, Ljubljana, Slovenia.
Department of Neurology, University Medical Centre Ljubljana, Zaloška 2, 1000, Ljubljana, Slovenia.
BMC Infect Dis. 2018 Aug 3;18(1):365. doi: 10.1186/s12879-018-3270-y.
Doxycycline is one of the recommended antibiotics for treating erythema migrans (EM). Since EM predominantly occurs during summer, the potential of doxycycline to induce photosensitivity is of concern. In studies on the efficacy of doxycycline for treating relatively small numbers of patients with EM, the reported frequency of photosensitivity has varied from none to 15%. The aim of this study was to elucidate the frequency and clinical symptoms of doxycycline-induced photosensitivity in a large cohort of patients with EM treated in a single medical centre.
Prospectively collected data on adverse events were analysed in adult patients with EM treated with doxycycline 100 mg twice daily for 10-15 days.
Photosensitivity reactions ranging from itching and burning sensations to transient mild erythema of sun-exposed skin were documented in 16/858 (1.9, 95% CI 1.1-3.0%) patients and appeared from June to October with highest frequency in July. These adverse events were more frequent in patients treated for 14 or 15 days (16/750 [2.1%]; 95% CI 1.2-3.4%) than in those treated for 10 days (0/108 [0%]; 95% CI 0.0-3.4%); however, the difference was not significant (P = 0.24). Women were more often affected than men (13/475 [2.7%], 95% CI 1.5-4.6% versus 3/383 [0.8%], 95% CI 0.2-2.3%; P = 0.04). Of the 16 patients who developed photosensitivity, 13 did not adhere to the recommendation to avoid sun exposure. None of the patients had any long-term sequelae of photosensitivity.
Photosensitivity reactions in adult patients with EM treated with doxycycline 100 mg twice daily for 10-15 days occurred rarely, were not severe, and had no long-term sequelae.
Registered at http://clinicaltrials.gov , Identifiers NCT00910715, May 28th 2009, NCT01163994, July 13th 2010 and NCT03584919, June 19th 2018 retrospectively registered.
多西环素是治疗游走性红斑(EM)的推荐抗生素之一。由于 EM 主要发生在夏季,因此多西环素引起光敏感性的可能性令人担忧。在研究多西环素治疗相对少数 EM 患者的疗效时,报告的光敏感性频率从无到 15%不等。本研究的目的是阐明在单一医疗中心治疗的大量 EM 患者中,多西环素诱导的光敏感性的频率和临床症状。
对接受多西环素 100mg 每日两次治疗 10-15 天的 EM 成年患者进行前瞻性收集不良事件数据。
16/858(1.9,95%CI 1.1-3.0%)名患者出现了从瘙痒和烧灼感到短暂轻度暴露于阳光下的红斑的光过敏反应,这些反应发生在 6 月至 10 月,7 月发生率最高。这些不良反应在治疗 14 或 15 天的患者中比治疗 10 天的患者更常见(16/750[2.1%];95%CI 1.2-3.4%比 0/108[0%];95%CI 0.0-3.4%);然而,差异无统计学意义(P=0.24)。女性比男性更容易受到影响(13/475[2.7%],95%CI 1.5-4.6%比 3/383[0.8%],95%CI 0.2-2.3%;P=0.04)。在发生光过敏的 16 名患者中,有 13 名未遵守避免阳光照射的建议。没有患者出现光过敏的任何长期后遗症。
接受多西环素 100mg 每日两次治疗 10-15 天的 EM 成年患者很少出现光过敏反应,且反应不严重,无长期后遗症。
在 http://clinicaltrials.gov 注册,标识符 NCT00910715,2009 年 5 月 28 日,NCT01163994,2010 年 7 月 13 日,NCT03584919,2018 年 6 月 19 日回溯性注册。